Biotech Values

[DewDiligence]

AGN moves Botox to phase-3 in depression despite tepid phase-2 data and lack of dose response:

Allergan To Test Botox For Depression Despite Mixed Results $AGN https://t.co/qqOS36eqLv

— Matthew Herper (@matthewherper) April 5, 2017

Efficacy comparison of combined 30U/50U Botox arms vs combined pbo arms not statsig or PR would surely have said so. That's big problem,IMO.

— Roy Friedman (@DewDiligence) April 5, 2017

AGN blames the lack of a dose response on the use of dual placebo arms, but that excuse does not hold water, IMO. More on this in the next post.